Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.35 |
| ▸ | MMP8 known ✓ | P22894 | 2/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.30 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.30 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.30 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.30 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.30 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5310131 | 1.00 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28549943 | 1.00 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28549945 | 1.00 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10544160 | 0.98 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10544179 | 0.98 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6874923 | 0.87 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3804263 | 0.87 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9582700 | 0.87 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3738082 | 0.87 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9582091 | 0.87 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4114836-B1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-115190878-B | Crystalline hydrates of JAK inhibitor compounds | 施万生物制药研发IP有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| EP-3837258-B1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230322774-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11702415-B2 | Crystalline hydrate of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3837010-B1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558611-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004039803-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | IMPDH1, POLA1, POLB | GAA 141/4885ADRA1A 4270/4885MMP8 1359/4885 |
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | GAA 2172/4885ADRA1A 2465/4885MMP8 2388/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | GAA 118/4885ADRA1A 4544/4885MMP8 1052/4885 |
| US-20230322774-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | GAA 2172/4885ADRA1A 2465/4885MMP8 2388/4885 |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | GAA 2337/4885ADRA1A 4310/4885MMP8 2087/4885 |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | GAA 47/4885ADRA1A 3111/4885MMP8 2524/4885 |
| US-12122773-B2 | Crystalline hydrate of a JAK inhibitor compound | JAK1, JAK2, JAK3 | GAA 2068/4885ADRA1A 3177/4885MMP8 1360/4885 |
| US-11702415-B2 | Crystalline hydrate of a JAK inhibitor compound | JAK1, JAK2, JAK3 | GAA 2068/4885ADRA1A 3177/4885MMP8 1360/4885 |
| US-20240025897-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | GAA 2068/4885ADRA1A 3177/4885MMP8 1360/4885 |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | GAA 97/4885ADRA1A 4614/4885MMP8 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.